Jazz Pharmaceuticals plc, of Dublin, and Concert Pharmaceuticals Inc., of Lexington, Mass., disclosed results from the recently completed phase I trial with JZP-386, a deuterium-containing analogue of sodium oxybate, evaluating the safety, pharmacokinetics and pharmacodynamics (PD) in 30 healthy volunteers.